Transanal Total Mesorectal Excision: Is There a Real Advantage? The Baltic View.
Minimally invasive
Rectal cancer
Surgery
Total mesorectal excision
taTME
Journal
Visceral medicine
ISSN: 2297-4725
Titre abrégé: Visc Med
Pays: Switzerland
ID NLM: 101681546
Informations de publication
Date de publication:
Jun 2019
Jun 2019
Historique:
entrez:
2
8
2019
pubmed:
2
8
2019
medline:
2
8
2019
Statut:
ppublish
Résumé
The novel surgical procedure transanal total mesorectal excision (taTME) has rapidly become an interest of research in order to overcome the shortcomings of laparoscopic surgery in the treatment of middle and low rectal cancer. taTME is a new natural orifice transluminal endoscopic surgery modality combining three rectal surgery techniques. A retrospective clinical study was conducted in a single centre for a period of 3 years, and herein we report on our first 25 taTME procedures in patients with middle and lower third rectal adenocarcinoma. The main demographics were evaluated. The mean age of patients was 64 ± 12 years. There were predominantly males (72%) and 7 female patients (28%) with an average body mass index of 29 ± 4.8 kg/m Our results nicely demonstrate that taTME can be safely performed with acceptable perioperative complications in patients with middle or lower third rectal cancer. In addition, the perioperative morbidity is also acceptable. However, taTME remains a technically highly demanding operation but is feasible and safe after the appropriate experience is gained. Nevertheless, larger multi-centre prospective randomised studies are ongoing to confirm the safety and to verify oncological results when compared to laparoscopic rectal surgery.
Sections du résumé
BACKGROUND
BACKGROUND
The novel surgical procedure transanal total mesorectal excision (taTME) has rapidly become an interest of research in order to overcome the shortcomings of laparoscopic surgery in the treatment of middle and low rectal cancer. taTME is a new natural orifice transluminal endoscopic surgery modality combining three rectal surgery techniques.
METHODS
METHODS
A retrospective clinical study was conducted in a single centre for a period of 3 years, and herein we report on our first 25 taTME procedures in patients with middle and lower third rectal adenocarcinoma.
RESULTS
RESULTS
The main demographics were evaluated. The mean age of patients was 64 ± 12 years. There were predominantly males (72%) and 7 female patients (28%) with an average body mass index of 29 ± 4.8 kg/m
CONCLUSION
CONCLUSIONS
Our results nicely demonstrate that taTME can be safely performed with acceptable perioperative complications in patients with middle or lower third rectal cancer. In addition, the perioperative morbidity is also acceptable. However, taTME remains a technically highly demanding operation but is feasible and safe after the appropriate experience is gained. Nevertheless, larger multi-centre prospective randomised studies are ongoing to confirm the safety and to verify oncological results when compared to laparoscopic rectal surgery.
Identifiants
pubmed: 31367610
doi: 10.1159/000495309
pii: vis-0035-0145
pmc: PMC6616097
doi:
Types de publication
Journal Article
Langues
eng
Pagination
145-150Déclaration de conflit d'intérêts
The authors do not have any competing interests to declare regarding this article.
Références
Dis Colon Rectum. 2001 May;44(5):638-46
pubmed: 11357021
Am J Surg Pathol. 2002 Mar;26(3):350-7
pubmed: 11859207
Lancet. 2004 Apr 10;363(9416):1187-92
pubmed: 15081650
Lancet. 2005 May 14-20;365(9472):1718-26
pubmed: 15894098
Lancet Oncol. 2005 Jul;6(7):477-84
pubmed: 15992696
Ann Surg. 2008 Apr;247(4):642-9
pubmed: 18362627
J Am Coll Surg. 2009 Jan;208(1):48-52
pubmed: 19228502
Br J Surg. 2009 Nov;96(11):1348-57
pubmed: 19847867
Surg Endosc. 2010 May;24(5):1205-10
pubmed: 20186432
Lancet Oncol. 2013 Mar;14(3):210-8
pubmed: 23395398
Br J Surg. 2013 Sep;100(10):1357-67
pubmed: 23939848
Surg Endosc. 2014 Dec;28(12):3494-9
pubmed: 24972923
Surg Endosc. 2015 Feb;29(2):334-48
pubmed: 25007974
Ann Surg. 2015 Feb;261(2):221-7
pubmed: 25185463
Ann Surg Oncol. 2015 Aug;22(8):2615-23
pubmed: 25605511
N Engl J Med. 2015 Apr 2;372(14):1324-32
pubmed: 25830422
Surg Endosc. 2016 Feb;30(2):464-470
pubmed: 25921202
J Am Coll Surg. 2015 Aug;221(2):415-23
pubmed: 26206640
Colorectal Dis. 2016 Jan;18(1):19-36
pubmed: 26466751
Ann Surg Oncol. 2016 Apr;23(4):1169-76
pubmed: 26597369
Colorectal Dis. 2016 Jan;18(1):51-8
pubmed: 26603786
Colorectal Dis. 2016 Jun;18(6):570-7
pubmed: 26749148
Tech Coloproctol. 2016 Apr;20(4):227-34
pubmed: 26794213
Cir Esp. 2016 Apr;94(4):213-20
pubmed: 26875478
Tech Coloproctol. 2016 Aug;20(8):537-44
pubmed: 26993638
Tech Coloproctol. 2016 Jul;20(7):467-73
pubmed: 27178183
J Am Coll Surg. 2017 May;224(5):917-925
pubmed: 28024946
Dis Colon Rectum. 2017 Oct;60(10):1023-1031
pubmed: 28891845
Ann Surg. 2019 Apr;269(4):700-711
pubmed: 29315090
Colorectal Dis. 2018 Jun;20(6):O143-O151
pubmed: 29693307
Surg Endosc. 2019 Jan;33(1):94-102
pubmed: 29967990
Medicine (Baltimore). 2018 Jul;97(28):e11410
pubmed: 29995787
Br J Hosp Med. 1979 Sep;22(3):277-81
pubmed: 391315
Br J Surg. 1982 Oct;69(10):613-6
pubmed: 6751457
Dis Colon Rectum. 1994 Aug;37(8):754-9
pubmed: 8055718